Ind-Swift Laboratories Limited (NSE:INDSWFTLAB)

Market Cap	6.30B
Revenue (ttm)	4.63B
Net Income (ttm)	3.54B
Shares Out	59.09M
EPS (ttm)	60.05
PE Ratio	1.78
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,143
Average Volume	297,351
Open	107.17
Previous Close	106.64
Day's Range	103.01 - 109.00
52-Week Range	68.72 - 186.00
Beta	0.44
RSI	51.04
Earnings Date	Aug 8, 2025

About Ind-Swift Laboratories

Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson’s disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticance...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 47
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: INDSWFTLAB

Financial Performance

In 2023, Ind-Swift Laboratories's revenue was 12.97 billion, an increase of 6.69% compared to the previous year's 12.16 billion. Earnings were 4.21 billion, an increase of 784.44%.